PL2252628T3 - Koniugaty antagonistów peptydowych analogu bombezyny - Google Patents

Koniugaty antagonistów peptydowych analogu bombezyny

Info

Publication number: PL2252628T3
Authority: PL; Poland
Prior art keywords: bombezin; peptide antagonists; analog peptide; analog; antagonists
Prior art date: 2008-03-07

Application number

PL09717301T

Other languages

English (en)

Inventor

Helmut Maecke

Jean Claude Reubi

Rosalba Mansi

Original Assignee

Universitätsspital Basel

Universität Bern

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-03-07

Filing date

2009-02-27

Publication date

2017-07-31

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39677415&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2252628(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2009-02-27 Application filed by Universitätsspital Basel, Universität Bern filed Critical Universitätsspital Basel

2017-07-31 Publication of PL2252628T3 publication Critical patent/PL2252628T3/pl

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
- C07K17/14—Peptides being immobilised on, or in, an inorganic carrier
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
- C07K7/086—Bombesin; Related peptides

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Epidemiology (AREA)
Physics & Mathematics (AREA)
Optics & Photonics (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Inorganic Chemistry (AREA)
Engineering & Computer Science (AREA)
Oil, Petroleum & Natural Gas (AREA)
Bioinformatics & Cheminformatics (AREA)
Oncology (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

PL09717301T 2008-03-07 2009-02-27 Koniugaty antagonistów peptydowych analogu bombezyny PL2252628T3 (pl)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP08075180A EP2100900A1 (en)	2008-03-07	2008-03-07	Bombesin analog peptide antagonist conjugates
EP09717301.7A EP2252628B1 (en)	2008-03-07	2009-02-27	Bombesin analog peptide antagonist conjugates

Publications (1)

Publication Number	Publication Date
PL2252628T3 true PL2252628T3 (pl)	2017-07-31

Family

ID=39677415

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL09717301T PL2252628T3 (pl)	2008-03-07	2009-02-27	Koniugaty antagonistów peptydowych analogu bombezyny

Country Status (33)

Country	Link
US (2)	US9035023B2 (pl)
EP (2)	EP2100900A1 (pl)
JP (1)	JP5784911B2 (pl)
KR (2)	KR20160128425A (pl)
CN (1)	CN101965358B (pl)
AR (1)	AR070809A1 (pl)
AU (1)	AU2009221204C1 (pl)
BR (1)	BRPI0909823B1 (pl)
CA (1)	CA2717427C (pl)
CL (1)	CL2009000537A1 (pl)
CO (1)	CO6290707A2 (pl)
CR (1)	CR11671A (pl)
CY (1)	CY1118687T1 (pl)
DK (1)	DK2252628T3 (pl)
DO (1)	DOP2010000269A (pl)
EC (1)	ECSP10010467A (pl)
ES (1)	ES2615805T3 (pl)
HU (1)	HUE032980T2 (pl)
IL (1)	IL207264A (pl)
MX (1)	MX2010009843A (pl)
NZ (1)	NZ587795A (pl)
PA (1)	PA8818501A1 (pl)
PE (1)	PE20091753A1 (pl)
PL (1)	PL2252628T3 (pl)
PT (1)	PT2252628T (pl)
RU (1)	RU2523531C2 (pl)
SI (1)	SI2252628T1 (pl)
SV (1)	SV2010003660A (pl)
TW (1)	TWI515011B (pl)
UA (1)	UA103314C2 (pl)
UY (1)	UY31693A (pl)
WO (1)	WO2009109332A1 (pl)
ZA (1)	ZA201006385B (pl)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2380596A1 (en)	2010-04-20	2011-10-26	Technische Universität München	Cyclopentapeptide derivatives and uses thereof
EP2380597A1 (en)	2010-04-20	2011-10-26	Technische Universität München	Cyclopeptide derivatives and uses thereof
EA026443B1 (ru) *	2010-11-22	2017-04-28	Пирамаль Имэджинг Са	Меченныелютецием аналоги бомбезина для лучевой терапии
EP2710027A1 (en) *	2011-05-19	2014-03-26	Universitätsspital Basel	Bombesin receptor targeting peptide incorporating a 1, 2, 3-triazole group in the backbone for preparing in vivo diagnostic and therapeutic agents
KR102190005B1 (ko)	2012-09-25	2020-12-15	어드밴스드 액셀러레이터 애플리케이션즈 유에스에이, 인코퍼레이티드.	Grpr-양성 암의 검출, 진단과 치료를 위한 grpr-길항제
EP2740726A1 (en)	2012-12-07	2014-06-11	3B Pharmaceuticals GmbH	Neurotensin receptor ligands
EP2970154B1 (en) *	2013-03-13	2021-07-07	The U.S.A. As Represented By The Secretary, Department Of Health And Human Services	Tetrahydroxamate chelators of zirconium89 and niobium90 for use in diagnostic applications
US20150217006A1 (en) *	2014-02-06	2015-08-06	Immunomedics, Inc.	Al-f-18-labeled, al-f-19-labeled and ga-68-labeled gastrin-releasing peptide receptor (grpr)-antagonists for imaging of prostate cancer
CN106573959B (zh)	2014-06-06	2022-03-25	慕尼黑工业大学	修饰的环五肽及其用途
EP2954934A1 (en)	2014-06-11	2015-12-16	3B Pharmaceuticals GmbH	Conjugate comprising a neurotensin receptor ligand and use thereof
EP2954933A1 (en)	2014-06-10	2015-12-16	3B Pharmaceuticals GmbH	Conjugate comprising a neurotensin receptor ligand
CA2949936C (en)	2014-06-10	2022-10-18	3B Pharmaceuticals Gmbh	Conjugate comprising a neurotensin receptor ligand and use thereof
ES2883347T3 (es)	2014-06-16	2021-12-07	Codexis Inc	Composiciones y procedimientos para atenuar y prevenir la inflamación intestinal debida a la presencia de antígenos alimentarios peptídicos en un intestino
CN104610431B (zh) *	2014-11-26	2017-12-15	南京市第一医院	一种多肽及其应用
US10857214B2 (en)	2015-12-16	2020-12-08	Codexis, Inc.	Compositions and methods for treating gluten intolerance and disorders arising therefrom
EP3279197A1 (en)	2016-08-03	2018-02-07	Friedrich-Alexander-Universität Erlangen-Nürnberg	Diagnosis, treatment and prevention of neurotensin receptor-related conditions
WO2018126183A2 (en) *	2016-12-29	2018-07-05	The General Hospital Corporation	Her3 peptides for imaging and radiotherapy
CA3050094C (en)	2017-01-12	2024-01-02	Radiomedix Inc.	Treatment of cancer cells overexpressing somatostatin receptors using ocreotide derivatives chelated to radioisotopes
WO2018204872A2 (en) *	2017-05-05	2018-11-08	Fusion Pharmaceuticals Inc.	Igf-1r monoclonal antibodies and uses thereof
RU2681318C1 (ru) *	2017-11-24	2019-03-06	Федеральное государственное бюджетное учреждение науки институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова Российской академии наук (ИБХ РАН)	Способ получения иммуносупрессорного пептида Abu-TGIRIS-Abu, меченного ионом Gd3+
AU2019469641B2 (en) *	2018-11-13	2025-04-03	Provincial Health Services Authority	Radiolabeled bombesin-derived compounds for in vivo imaging of gastrin-releasing peptide receptor (GRPR) and treatment of GRPR-related disorders
CN118955620A (zh)	2019-07-08	2024-11-15	3B制药有限公司	包含成纤维细胞活化蛋白配体的化合物及其用途
EP3763726A1 (en)	2019-07-08	2021-01-13	3B Pharmaceuticals GmbH	Compounds comprising a fibroblast activation protein ligand and use thereof
MX2022007260A (es) *	2019-12-19	2022-07-19	Univ Muenchen Tech	Compuestos con farmacocinetica mejorada para la obtencion de imagenes y la terapia del cancer.
WO2021250240A1 (en)	2020-06-12	2021-12-16	Orano	Diaza-18-crown-6 derivative useful for chelating radium, conjugate and radium chelate comprising the same, and uses thereof
EP3973999A1 (en) *	2020-09-28	2022-03-30	Orano Med	Conjugate or its salt comprising a gastrin-releasing peptide receptor antagonist and uses thereof
WO2022123462A1 (en)	2020-12-09	2022-06-16	3B Pharmaceuticals Gmbh	Radiolabelled prostate specific membrane antigen (psma) inhibitors and use thereof
EP4050018A1 (en)	2021-01-07	2022-08-31	3B Pharmaceuticals GmbH	Compounds comprising a fibroblast activation protein ligand and use thereof
KR20230173150A (ko)	2021-04-20	2023-12-26	테라파워, 엘엘씨	Ac-225 생성용 티타니아 기반 발생기
EP4448544A2 (en)	2021-12-17	2024-10-23	3B Pharmaceuticals GmbH	Carbonic anhydrase ix ligands
AU2023239751A1 (en)	2022-03-25	2024-09-05	Provincial Health Services Authority	Radiolabeled compounds for in vivo imaging of gastrin-releasing peptide receptor (grpr) and treatment of grpr-related disorders
US20260083865A1 (en)	2022-09-07	2026-03-26	3B Pharmaceuticals Gmbh	Prostate specific membrane antigen (psma) ligands and use thereof
CN117919452B (zh) *	2023-03-09	2026-05-12	中国科学院宁波材料技术与工程研究所	一种亚细胞器主动靶向成像探针及其制备方法
CN118772232B (zh) *	2023-04-10	2025-08-22	湖南中晟全肽生物科技股份有限公司	蛙皮素类多肽化合物及其用途
EP4455159A1 (en)	2023-04-25	2024-10-30	3B Pharmaceuticals GmbH	Gastric inhibitory peptide receptor ligands with bio-distribution modifier
WO2025054727A1 (en) *	2023-09-13	2025-03-20	Provincial Health Services Authority	Radiolabeled compounds for in vivo imaging of gastrin-releasing peptide receptor (grpr) and treatment of grpr-related disorders
CN120019818A (zh) *	2023-11-20	2025-05-20	湖南中晟全肽生物科技股份有限公司	一种多肽偶联药物及其制备方法和用途
AU2024386376A1 (en)	2023-11-21	2026-05-28	3B Pharmaceuticals Gmbh	P-cadherin ligands
WO2025119203A1 (zh) *	2023-12-05	2025-06-12	烟台蓝纳成生物技术有限公司	一种异二聚体放射性核素偶联药物、制备及其应用
WO2025217074A1 (en) *	2024-04-08	2025-10-16	Radionetics Oncology, Inc.	Kisspeptin receptor (kiss1r) targeted therapeutics and uses thereof
CN121991166A (zh) *	2024-11-05	2026-05-08	成都纽瑞特医疗科技股份有限公司	放射性配体化合物及其用途

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4885363A (en)	1987-04-24	1989-12-05	E. R. Squibb & Sons, Inc.	1-substituted-1,4,7-triscarboxymethyl-1,4,7,10-tetraazacyclododecane and analogs
US5021556A (en)	1987-07-22	1991-06-04	Neorx Corporation	Method of radiolabeling chelating compounds comprising sulfur atoms with metal radionuclides
US5075099A (en)	1988-05-31	1991-12-24	Neorx Corporation	Metal radionuclide chelating compounds for improved chelation kinetics
US5364613A (en)	1989-04-07	1994-11-15	Sieving Paul F	Polychelants containing macrocyclic chelant moieties
US5686410A (en) *	1989-07-20	1997-11-11	Novartis Ag	Polypeptide derivatives
ATE120374T1 (de) *	1989-07-20	1995-04-15	Sandoz Ag	Markierte polypeptidderivate.
US5367080A (en)	1990-11-08	1994-11-22	Sterling Winthrop Inc.	Complexing agents and targeting radioactive immunoreagents useful in therapeutic and diagnostic imaging compositions and methods
US5369094A (en)	1990-11-29	1994-11-29	The Administrators Of The Tulane Educational Fund	Polypeptide bombesin antagonists
US5965107A (en)	1992-03-13	1999-10-12	Diatide, Inc.	Technetium-99m labeled peptides for imaging
US7060247B2 (en)	1997-04-22	2006-06-13	The Curators Of The University Of Missouri	Gastrin receptor-avid peptide conjugates
WO1998047524A1 (en)	1997-04-22	1998-10-29	Curators Of The University Of Missouri	Gastrin receptor-avid peptide conjugates
US5886142A (en)	1997-05-20	1999-03-23	Thomas Jefferson University	Radiolabeled thrombus imaging agents
EP1042280A2 (en)	1997-12-24	2000-10-11	Vertex Pharmaceuticals Incorporated	Prodrugs of aspartyl protease inhibitors
US6436989B1 (en)	1997-12-24	2002-08-20	Vertex Pharmaceuticals, Incorporated	Prodrugs of aspartyl protease inhibitors
AU2012199A (en)	1997-12-24	1999-07-19	Vertex Pharmaceuticals Incorporated	Prodrugs of aspartyl protease inhibitors
AU2010299A (en)	1997-12-24	1999-07-19	Vertex Pharmaceuticals Incorporated	Prodrugs os aspartyl protease inhibitors
GR1003661B (el) *	2000-05-25	2001-09-05	Εθνικο Κεντρο Ερευνας Φυσικων Επιστημων (Εκεφε) "Δημοκριτος"...	ΣΥΝΘΕΣΗ, ΒΙΟΛΟΓΙΚΗ ΚΑΙ ΠΡΟΚΛΙΝΙΚΗ ΑΞΙΟΛΟΓΗΣΗ ΑΝΑΛΟΓΩΝ ΤΗΣ (D-Phe6, Leu-NHEt13, des-Met14)-ΒΟΜΒΕΣΙΝΗΣ (6-14)ΤΡΟΠΟΠΟΙΗΜΕΝΩΝ ΜΕ ΠΑ ΡΑΓΩΓΑ ΤΟΥ 1,4,8,11-ΤΕΤΡΑΑΖΑΕΝΔΕΚΑΝΙΟΥ(1,4,8,11-TETRAAZAUNDECAN E)ΚΑΙ ΕΠΙΣΗΜΑΣΜΕΝΩΝ ΜΕ ΤΕΧΝΗΤΙΟ-99M- ΓΙΑ ΕΦΑΡΜΟΓΗ ΣΤΗΝ ΟΓΚΟΛΟΓ
IL155773A0 (en) *	2000-12-20	2003-12-23	Warner Lambert Co	Novel uses of non-peptide bombesin receptor antagonists for treating anxiety and panic disorders
US20080008649A1 (en)	2003-01-13	2008-01-10	Bracco Imaging S.P.A.	Gastrin Releasing Peptide Compounds
US7850947B2 (en)	2003-01-13	2010-12-14	Bracco Imaging S.P.A.	Gastrin releasing peptide compounds
US7226577B2 (en)	2003-01-13	2007-06-05	Bracco Imaging, S. P. A.	Gastrin releasing peptide compounds
US7922998B2 (en) *	2003-01-13	2011-04-12	Bracco Imaging S.P.A.	Gastrin releasing peptide compounds
CN100418585C (zh) *	2003-07-24	2008-09-17	伯拉考成像股份公司	稳定的放射性药物组合物及制备方法
WO2007109475A2 (en)	2006-03-16	2007-09-27	Bracco Imaging S.P.A.	Chelation of metals to thiol groups using in situ reduction of disulfide-containing compounds by phosphines
EA026443B1 (ru) *	2010-11-22	2017-04-28	Пирамаль Имэджинг Са	Меченныелютецием аналоги бомбезина для лучевой терапии

2008
- 2008-03-07 EP EP08075180A patent/EP2100900A1/en not_active Withdrawn
2009
- 2009-02-27 CA CA2717427A patent/CA2717427C/en active Active
- 2009-02-27 KR KR1020167029634A patent/KR20160128425A/ko not_active Withdrawn
- 2009-02-27 JP JP2010549043A patent/JP5784911B2/ja active Active
- 2009-02-27 UA UAA201011560A patent/UA103314C2/ru unknown
- 2009-02-27 ES ES09717301.7T patent/ES2615805T3/es active Active
- 2009-02-27 EP EP09717301.7A patent/EP2252628B1/en active Active
- 2009-02-27 DK DK09717301.7T patent/DK2252628T3/en active
- 2009-02-27 BR BRPI0909823-2A patent/BRPI0909823B1/pt active IP Right Grant
- 2009-02-27 CN CN200980107992.5A patent/CN101965358B/zh active Active
- 2009-02-27 AU AU2009221204A patent/AU2009221204C1/en active Active
- 2009-02-27 SI SI200931607A patent/SI2252628T1/sl unknown
- 2009-02-27 KR KR1020107022308A patent/KR101734553B1/ko active Active
- 2009-02-27 HU HUE09717301A patent/HUE032980T2/en unknown
- 2009-02-27 US US12/921,209 patent/US9035023B2/en active Active
- 2009-02-27 NZ NZ587795A patent/NZ587795A/en unknown
- 2009-02-27 RU RU2010140846/04A patent/RU2523531C2/ru active
- 2009-02-27 PT PT97173017T patent/PT2252628T/pt unknown
- 2009-02-27 PL PL09717301T patent/PL2252628T3/pl unknown
- 2009-02-27 MX MX2010009843A patent/MX2010009843A/es not_active Application Discontinuation
- 2009-02-27 WO PCT/EP2009/001403 patent/WO2009109332A1/en not_active Ceased
- 2009-03-06 PA PA20098818501A patent/PA8818501A1/es unknown
- 2009-03-06 TW TW098107446A patent/TWI515011B/zh active
- 2009-03-06 CL CL2009000537A patent/CL2009000537A1/es unknown
- 2009-03-06 AR ARP090100799A patent/AR070809A1/es not_active Application Discontinuation
- 2009-03-06 PE PE2009000339A patent/PE20091753A1/es not_active Application Discontinuation
- 2009-03-06 UY UY0001031693A patent/UY31693A/es not_active Application Discontinuation
2010
- 2010-07-28 IL IL207264A patent/IL207264A/en active IP Right Grant
- 2010-09-06 CO CO10110036A patent/CO6290707A2/es not_active Application Discontinuation
- 2010-09-06 ZA ZA2010/06385A patent/ZA201006385B/en unknown
- 2010-09-07 EC EC2010010467A patent/ECSP10010467A/es unknown
- 2010-09-07 CR CR11671A patent/CR11671A/es not_active Application Discontinuation
- 2010-09-07 SV SV2010003660A patent/SV2010003660A/es not_active Application Discontinuation
- 2010-09-07 DO DO2010000269A patent/DOP2010000269A/es unknown
2015
- 2015-03-27 US US14/671,106 patent/US20150265733A1/en not_active Abandoned
2017
- 2017-02-07 CY CY20171100170T patent/CY1118687T1/el unknown

Also Published As

Publication number	Publication date
EP2100900A1 (en)	2009-09-16
NZ587795A (en)	2012-07-27
EP2252628B1 (en)	2016-12-28
AU2009221204C1 (en)	2016-12-08
ECSP10010467A (es)	2010-10-30
DOP2010000269A (es)	2010-10-31
IL207264A0 (en)	2011-08-01
PE20091753A1 (es)	2009-12-13
KR20160128425A (ko)	2016-11-07
BRPI0909823B1 (pt)	2022-04-19
SI2252628T1 (sl)	2017-05-31
HUE032980T2 (en)	2017-11-28
AR070809A1 (es)	2010-05-05
CY1118687T1 (el)	2017-07-12
ES2615805T3 (es)	2017-06-08
EP2252628A1 (en)	2010-11-24
AU2009221204A1 (en)	2009-09-11
CA2717427A1 (en)	2009-09-11
CL2009000537A1 (es)	2010-07-19
UY31693A (es)	2010-01-05
UA103314C2 (ru)	2013-10-10
ZA201006385B (en)	2016-10-26
RU2523531C2 (ru)	2014-07-20
US9035023B2 (en)	2015-05-19
DK2252628T3 (en)	2017-02-06
JP2011515338A (ja)	2011-05-19
MX2010009843A (es)	2011-03-04
PA8818501A1 (es)	2010-04-21
US20110097266A1 (en)	2011-04-28
CN101965358B (zh)	2019-09-03
IL207264A (en)	2017-02-28
RU2010140846A (ru)	2012-04-20
JP5784911B2 (ja)	2015-09-24
AU2009221204B2 (en)	2013-09-05
KR20110014565A (ko)	2011-02-11
WO2009109332A1 (en)	2009-09-11
CO6290707A2 (es)	2011-06-20
KR101734553B1 (ko)	2017-05-11
BRPI0909823A2 (pt)	2019-03-06
PT2252628T (pt)	2017-02-10
CN101965358A (zh)	2011-02-02
TWI515011B (zh)	2016-01-01
SV2010003660A (es)	2011-02-17
TW200944239A (en)	2009-11-01
US20150265733A1 (en)	2015-09-24
CR11671A (es)	2010-11-01
CA2717427C (en)	2016-02-23

Publication	Publication Date	Title
HUS2200025I1 (hu)	2022-06-28	C5AR antagonisták
NO2022016I1 (no)	2022-05-25	Anifrolumab
DK2160221T3 (da)	2011-09-19	Cykliske peptid-CXCR4-antagonister
DK2515928T3 (da)	2014-08-25	Oxyntomodulin peptidanalog
BRPI0911743A2 (pt)	2015-07-07	"peptídeo"
IL207264A0 (en)	2011-08-01	Bonbesin analog peptide antagonist conjugates
BRPI0908116A2 (pt)	2015-10-06	pulverizador
HRP20151108T1 (xx)	2015-11-20	Antagonisti nogo-receptora
HRP20151120T1 (xx)	2015-11-20	Polipeptid ace2
DK2171053T3 (da)	2014-07-28	Natriuretiske polypeptider
PL2465864T3 (pl)	2015-03-31	Szczepionki z peptydem pochodzącym z Eph4
DK3115370T3 (da)	2019-07-29	Biologisk aktive peptider
EP2321062A4 (en)	2014-10-29	Sprayer
BRPI1012728A2 (pt)	2016-04-05	uso de tripeptídeos
EP2437770A4 (en)	2013-11-06	ANTIMICROBIAL PEPTIDES
BRPI1010661A2 (pt)	2016-03-15	peptídeo
BRPI0910722A2 (pt)	2015-09-29	columbário
HRP20150195T1 (xx)	2015-06-05	Antibakterijski peptidi
BRPI0908008A2 (pt)	2015-08-18	Farmacóforo dual - pde4-antagonistas muscarínicos
BR112012005119A2 (pt)	2016-11-22	novos antagonistas de hepcidina etanodiaminas
EP2280988A4 (en)	2011-08-10	ANGIOGENIC PEPTIDE
IT1395137B1 (it)	2012-09-05	Nuovi peptidi antipatogeni
BRPI0907519A2 (pt)	2015-07-28	Antagonistas farmacoforos-pde4-muscarínicos duais
EP2252310A4 (en)	2011-09-07	HETEROCYCLIC PEPTIDE KETOAMIDE
EP2195338A4 (en)	2010-11-03	N-TERMINAL MODIFIED INTERFERON ALPHA